Repurposing ivacaftor to attenuate LPS-induced acute lung injury: evidence from a non-cystic fibrosis model.

Front Pharmacol · 2026 · PMC13265339 · PMID 42305437

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

At 72 h, ivacaftor IT administration showed a trend of reducing NK cells, which was likely due to insufficient concentrations of ivacaftor because of metabolisation.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.